诺华成功收购Avidity Biosciences,强化神经科学后期产品管线

投资观察
Feb 27

2月27日,诺华公司宣布已完成对Avidity Biosciences的收购。此次交易将显著增强诺华在神经科学领域的后期产品管线,并推动其扩展RNA(xRNA)战略的实施。

诺华预计,通过此次收购,公司将在2030年前释放数十亿美元的商业机会。同时,这一举措进一步强化了诺华的后期产品管线,有望支持公司在2025年至2030年间实现按固定汇率计算约5%至6%的净销售额复合年增长率,并巩固其中长期增长前景。

根据收购条款,Avidity Biosciences普通股的持有者有权获得每股72.00美元的现金对价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10